Fidelity Investments
MBRX icon

Fidelity Investments’s Moleculin Biotech MBRX Stock Holding History

Fidelity Investments’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$7 – 5665
2026
Q1 		$7 Buy
+3
New +$10 ﹤0.01% 5383
2025
Q2 		– Sell
-1
Closed -$33 – 5431
2025
Q1 		$33 Buy
+1
New +$34 ﹤0.01% 5187
2023
Q4 		– Hold
0
– -$1 – 5565
2023
Q3 		– Hold
0
– – – 5259
2023
Q2 		– Hold
0
– – – 5351
2023
Q1 		– Hold
0
– – – 5235
2022
Q4 		– Hold
0
– – – 5318
2022
Q3 		– Hold
0
– – – 5204
2022
Q2 		– Hold
0
– – – 5264

Other funds holding MBRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments's MBRX Position: Q2 2026 in Review

Fidelity Investments sold out of Moleculin Biotech (MBRX) in Q2 2026, closing a stake of 3 shares — an estimated $7 sold.

Fidelity Investments first reported a position in MBRX in Q1 2025 and held it in 2 quarters. The position peaked at $33 in Q1 2025. 18 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.

  • Fidelity Investments reported no remaining Moleculin Biotech position as of Q2 2026 after selling out during the quarter.
  • Fidelity Investments sold 3 Moleculin Biotech shares in Q2 2026, an estimated $7.
  • Fidelity Investments first reported a position in Moleculin Biotech in Q1 2025 and held it in 2 quarters.
  • Fidelity Investments's Moleculin Biotech position peaked at $33 in Q1 2025.
  • 18 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.